Status:

COMPLETED

Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram

Lead Sponsor:

University of Utah

Collaborating Sponsors:

AlzChem, LLC

Conditions:

Major Depressive Disorder

Eligibility:

FEMALE

13-18 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to see if creatine, which is a naturally occurring chemical in the body, is effective for treating Major Depressive Disorder (MDD) in female teenagers. Creatine may have e...

Detailed Description

This is an open-label clinical trial of the investigational drug creatine, for augmentation treatment of female adolescents with Major Depressive Disorder (MDD) who have failed to respond to first-lin...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for Major Depressive Disorder Participants:
  • Participants must meet DSM-IV-TR criteria for Major Depressive Disorder, with current mood state depressed for ≥ 2 weeks.
  • Participants must be females
  • Participants must be between the age of 13 and 18 years.
  • Participants must have had an adequate trial of fluoxetine, defined as a trial of ≥ 8 weeks of treatment, with a dose of ≥ 40mg daily for ≥ 4 weeks. If the participant had a trial of 40mg daily and was unable to tolerate it, a dose of 20mg for ≥ 8 weeks is acceptable; OR
  • Participants must have had an adequate trial of escitalopram, defined as a trial of ≥ 8 weeks of treatment, with a dose of ≥ 20 mg daily for ≥ 4 weeks. If the participant had a trial of 20 mg daily and was unable to tolerate it, a dose of 10 mg for ≥ 8 weeks is acceptable.
  • Participants must have a CDRS-R score of ≥ 40 and a CGI-S score of ≥ 4.
  • Participants must be able to give informed consent or assent, and where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation.
  • Inclusion Criteria for Healthy Control Participants:
  • Participants must be females
  • Participants must be between the age of 13 and 18 years.
  • Participants must not meet DSM-IV-TR diagnostic criteria for a psychiatric or substance abuse disorder.
  • Participants must be able to give informed consent or assent and, where applicable, parent(s)/guardian(s) must be able to give informed permission for study participation.
  • Exclusion Criteria for Treatment-Resistant Major Depressive Disorder Participants:
  • Unstable co-morbid medical, neurological or psychiatric disorder.
  • Pre-existing renal disease.
  • Proteinuria or microalbuminuria.
  • Pregnant females, nursing mothers, or females of childbearing potential who are unable or unwilling to practice birth control during the study. Participants who are of child-bearing potential must have a negative urine pregnancy test before each MRI/MRS brain scan.
  • High risk for suicidal behavior, homicidal behavior or self-harm.
  • Adolescents who are unlikely to be able to comply with the study protocol.
  • DSM-IV-TR criteria for current substance abuse or substance dependence, with the exception of nicotine abuse or dependence.
  • Contraindication to MRI/MRS brain scans, such as ferromagnetic implants or claustrophobic anxiety.
  • Documented or suspected history of intellectual disability (Full-Scale I.Q. \< 70).
  • History of hypersensitivity to creatine monohydrate.
  • Exclusion Criteria for Healthy Controls:
  • Clinically significant psychiatric or substance abuse disorder.
  • Unstable medical or neurological illness.
  • Pregnancy, due to the unknown effects of MRI/MRS scanning on a developing fetus.
  • Females of childbearing potential who are unable or unwilling to practice contraception during the study.
  • Positive urine pregnancy test.
  • Contraindication to MRI/MRS scanning, such as ferromagnetic implant or claustrophobic anxiety.
  • Documented or suspected history of mental retardation (Full-Scale I.Q. \< 70).

Exclusion

    Key Trial Info

    Start Date :

    April 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2012

    Estimated Enrollment :

    13 Patients enrolled

    Trial Details

    Trial ID

    NCT00851006

    Start Date

    April 1 2009

    End Date

    December 1 2012

    Last Update

    May 12 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Utah

    Salt Lake City, Utah, United States, 84108